What
  • Acupuncture
  • Agriculture & Forestry Sector
  • Allergists
  • Arts, Entertainment & Recreation Sector
  • Assisted Living
  • Behavioral Health Services
  • Blood & Organ Banks
  • Business Services
  • Cardiology Department
  • Cardiovascular Intensive Care Unit
  • Chiropractor
  • Clinics
  • Consumer Services
  • Dental Laboratories
  • Dentistry
  • Dermatology
  • Dispensary or Pharmacy
  • Education Sector
  • Electric Utilities
  • Emergency & Other Outpatient Care Centers
  • Emergency Department
  • ENT Hospitals
  • Family Planning & Abortion Clinics
  • Finance & Insurance Sector
  • General Medical & Surgical Hospitals
  • Government
  • HealthCare
  • Heavy & Civil Engineering Construction
  • Hospices & Palliative Care Centers
  • Intensive Care Unit
  • Lodging
  • Management of Companies & Enterprises
  • Manufacturing
  • Media
  • Medical Records Department
  • Membership Organizations
  • Midwives
  • Mining
  • Natural Gas Distribution & Marketing
  • Neonatal Intensive Care Unit
  • Neurology
  • Nonprofit Institutions
  • Nonresidential Building Construction
  • Nursing Homes
  • Obstetrics and Gynecology
  • Oil & Gas Exploration & Production
  • Oil & Gas Field Services
  • Oil & Gas Well Drilling
  • Oncology
  • Ophthalmology
  • Others
  • Outpatient Departments
  • Pathology
  • Pediatric Intensive Care Unit
  • Physical Therapy
  • Plastic Surgeries
  • Private Households
  • Professional Services
  • Psychiatric Hospitals
  • Psychiatric Ward
  • Radiology
  • Real Estate
  • Rehabilitation Services
  • Religious Organizations
  • Rental & Leasing
  • Residential Construction Contractors
  • Restaurants, Bars & Food Services
  • Retail Sector
  • Sleep Disorder Clinics
  • Specialty Contractors
  • Specialty Hospitals
  • Teaching Hospitals
  • Technology
  • Transportation Services Sector
  • Veterinarians and Animal Hospitals
  • Water & Sewer Utilities
  • Wholesale Sector
Where
contacts Sign In

Genus Oncology

Genus Oncology

Novel immnotherapeutics that target the MUC1-C oncoprotien

Be the first to review

Our mission is the development of novel therapeutics for the treatment of patients with solid tumors and hematologic malignancies that express the highly prevalent MUC1 cancer target.   Genus has identified the “Achilles Heel” of MUC1, the MUC1-C subunit, and is developing agents that target this oncogenic transmembrane protein.

Company Metrics

  • 25
  • $5 million
  • Cancer treatment
todayTime TodayClosed Now!09:00 AM - 05:00 PM
  • Monday09:00 AM - 05:00 PM
  • Tuesday09:00 AM - 05:00 PM
  • Wednesday09:00 AM - 05:00 PM
  • Thursday09:00 AM - 05:00 PM
  • Friday09:00 AM - 05:00 PM
Expand

Contact with business owner

Your request has been submitted successfully.

building Own or work here? Claim Now! Claim Now!

Claiming your business Listing

Claim request is processed after verification..

Claim

Claim your business and connect to wider audience

Did you know the simplest way to crack a business deal is to connect to the decision-maker of a company?

Our sales associate can make this process easier for you
Connect now!
listing banner footer